Investors Buy High Volume of Karyopharm Therapeutics Call Options (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of unusually large options trading on Thursday. Stock investors bought 10,965 call options on the stock. This represents an increase of 817% compared to the typical volume of 1,196 call options.

Wall Street Analyst Weigh In

KPTI has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a report on Wednesday, December 17th. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $9.35 on Friday. The company has a market capitalization of $171.48 million, a P/E ratio of -0.56 and a beta of 0.21. The company has a 50 day simple moving average of $7.54 and a 200-day simple moving average of $6.58. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. As a group, research analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after purchasing an additional 790,417 shares in the last quarter. Ikarian Capital LLC boosted its position in Karyopharm Therapeutics by 1,897.9% in the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares during the period. Boothbay Fund Management LLC purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at approximately $1,064,000. Walleye Capital LLC acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter worth $704,000. Finally, Geode Capital Management LLC increased its position in shares of Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after acquiring an additional 94,445 shares during the period. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.